CASE REPORT article
Front. Oncol.
Sec. Breast Cancer
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1623700
This article is part of the Research TopicMolecular and Functional Profiling in Breast Cancer: Implications for Hereditary and Sporadic CasesView all 5 articles
Case report: Functional Validation of a Rare Variant BRCA1 c.5193+2dupT in a Family with Cancer History
Provisionally accepted- 1Department of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China
- 2Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, Sichuan, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: BRCA1 and BRCA2 genes are well-established tumor suppressors, crucial for maintaining genomic stability through their roles in DNA repair. Pathogenic variants in BRCA1/2 genes are implicated in increased susceptibility to breast and ovarian cancers. However, variant interpretation remains challenging due to the large size (>80 kb) of BRCA1/2 and the broad spectrum of variant forms, particularly for rare or recently identified variants lacking adequate population, functional or segregation data. Case Presentation: This report describes a case of high-grade serous ovarian carcinoma in a patient with a strong family history of cancer. Both her mother and sister died of ovarian cancer. Genetic testing identified the germline variant BRCA1 c.5193+2dupT both in the patient's tumor and peripheral blood samples, without other abnormalities detected in genomic homologous recombination deficiency assessment. Her daughter was identified as an unaffected carrier of this variant. Unfortunately, the BRCA1 status of deceased relatives could not be determined due to the unavailability of samples. Functional studies, including minigene splicing assay and transcript analysis, demonstrated that this variant induces a splicing error, specifically, an aberrant skipping of exon 18, resulting in dysfunction of the BRCA1-encoded protein. These findings provide a mechanistic explanation for the observed cancer susceptibility in this family. Conclusion: This case highlights a rare germline variant, BRCA1 c.5193+2dupT, in a family with a strong cancer history. In vitro functional assays confirmed that this variant induces exon 18 skipping through aberrant splicing, leading to dysfunction of BRCA1-encoded protein. To our knowledge, this is the first functional characterization of the variant BRCA1 c.5193+2dupT, and our data provide novel insights for risk assessment and precision treatment strategies in carriers of this variant.
Keywords: BRCA11, germline variant2, splicing error3, hereditary breast and ovarian cancer4, variantof uncertain significance5
Received: 06 May 2025; Accepted: 12 Sep 2025.
Copyright: © 2025 Dai, Wang and Dan-Qing. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Ping Wang, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, Sichuan, China
Wang Dan-Qing, Department of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.